Telix Pharmaceuticals Ltd
TLX14.060USD
+1.010+7.74%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Telix Pharmaceuticals Ltd Unternehmen
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
Unternehmensinformationen
BörsenkürzelTLX
Name des UnternehmensTelix Pharmaceuticals Ltd
IPO-datumNov 15, 2017
CEOMr. Kevin Richardson
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse55 Flemington Road
StadtMELBOURNE
BörseXetra
LandAustralia
Postleitzahl3051
Telefon61390933855
Websitehttps://telixpharma.com/
BörsenkürzelTLX
IPO-datumNov 15, 2017
CEOMr. Kevin Richardson
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 13 hours ago
Aktualisiert: 13 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Pier Capital, LLC
0.02%
Other
99.98%
Aktionäre
Aktionäre
Anteil
Pier Capital, LLC
0.02%
Other
99.98%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
0.03%
Other
99.97%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
9
52.71K
0.02%
+48.98K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Private Advisor Group LLC
10.14K
0%
+10.14K
--
Mar 31, 2025
UBS Financial Services, Inc.
3.65K
0%
-79.00
-2.12%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.90K
0%
+2.90K
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
2.73K
0%
+2.73K
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.15K
0%
+1.15K
--
Mar 31, 2025
EverSource Wealth Advisors, LLC
137.00
0%
+137.00
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
